WHIPPANY, N.J., Aug. 9, 2018 /PRNewswire/ -- Bayer today announced the appointment of Patrick Lockwood-Taylor as Regional President, Consumer Health, North America, effective August 13, 2018.
Patrick is a seasoned leader with more than 25 years in the consumer industry driving business growth by building categories and brands among intense competition and changing market dynamics. He joins from The Oneida Group where he served as CEO. Prior to assuming that role, he was Vice President of Personal Health Care North America and Global Digestive Wellness at Procter & Gamble (P&G) where he drove top and bottom line growth over many years.
Patrick started his career with P&G in foodservice in the United Kingdom and subsequently held roles of increasing responsibility across sales, marketing, commercial operations and general management in consumer packaged goods. Over the course of his career, he held multiple leadership positions in the United States and in other key geographies around the world, including in Asia and Africa.
"Patrick has a passion for innovation and an understanding of how to meet the needs of consumers and customers to accelerate growth," said Heiko Schipper, member of Bayer's Board of Management and President of Consumer Health. "His diverse experience, proven track record of collaborating with retail partners and leadership in times of change make him ideally suited to lead our important North American business in a time of unprecedented industry change."
Patrick succeeds Natalie Bartner. He will report directly to Heiko Schipper and become a member of the Consumer Health Executive Committee. Patrick will be based in Whippany, New Jersey, USA.
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2017, the Group employed around 99,800 people and had sales of EUR 35.0 billion. Capital expenditures amounted to EUR 2.4 billion, R&D expenses to EUR 4.5 billion. For more information, go to www.bayer.us.
Bayer® and the Bayer Cross® are registered trademarks of Bayer.
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.